Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-04-11 Sale | 2024-04-15 7:06 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 30,000 | $25.04 | $751,332 | 1,347,585 (Indirect Direct) | View |
| 2024-04-01 Sale | 2024-04-03 9:30 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $18.6 | $223,146 | 1,377,585 (Indirect Direct) | View |
| 2024-02-29 Sale | 2024-03-04 5:55 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $16.42 | $197,006 | 1,389,585 (Indirect Direct) | View |
| 2024-01-29 Sale | 2024-01-31 9:22 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $15.85 | $190,256 | 1,401,585 (Indirect Direct) | View |
| 2023-12-29 Sale | 2024-01-03 7:01 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 12,000 | $14.28 | $171,381 | 1,413,585 (Indirect Direct) | View |
| 2023-12-21 Sale | 2023-12-26 7:32 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 6,566 | $13.07 | $85,790 | 1,740,681 (Indirect Direct) | View |
| 2023-12-19 Sale | 2023-12-21 4:29 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 8,888 | $13.01 | $115,646 | 1,755,955 (Indirect Direct) | View |
| 2023-11-03 Sale | 2023-11-06 4:43 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 8,546 | $13.08 | $111,751 | 1,441,039 (Indirect Direct) | View |
| 2023-09-29 Sale | 2023-10-03 7:40 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 12,000 | $13.62 | $163,498 | 1,449,585 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-04-11 Exercise | 2024-04-15 7:06 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 30,000 | $1.12 | 1,347,585 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:06 pm | N/A 2030-06-16 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 30,000 | $0 | 1,347,585 (Direct) | View |
| 2024-04-01 Exercise | 2024-04-03 9:30 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $1.12 | 1,377,585 (Direct) | View |
| 2024-04-01 Exercise | 2024-04-03 9:30 pm | N/A 2030-06-16 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $0 | 1,377,585 (Direct) | View |
| 2024-02-29 Exercise | 2024-03-04 5:55 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $1.12 | 1,389,585 (Direct) | View |
| 2024-02-29 Exercise | 2024-03-04 5:55 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $0 | 1,389,585 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 9:00 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 185,000 | $0 | 185,000 (Direct) | View |
| 2024-01-29 Exercise | 2024-01-31 9:22 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $1.12 | 1,401,585 (Direct) | View |
| 2024-01-29 Exercise | 2024-01-31 9:22 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $0 | 1,401,585 (Direct) | View |
| 2023-12-29 Exercise | 2024-01-03 7:01 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 12,000 | $1.12 | 1,413,585 (Direct) | View |
| 2023-12-29 Exercise | 2024-01-03 7:01 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 12,000 | $0 | 1,413,585 (Direct) | View |
| 2023-12-21 Exercise | 2023-12-26 7:32 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 6,566 | $1.12 | 1,740,681 (Direct) | View |
| 2023-12-21 Exercise | 2023-12-26 7:32 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 6,566 | $0 | 1,740,681 (Direct) | View |
| 2023-12-19 Exercise | 2023-12-21 4:29 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 8,888 | $1.12 | 1,755,955 (Direct) | View |
| 2023-12-19 Exercise | 2023-12-21 4:29 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 8,888 | $0 | 1,755,955 (Direct) | View |
| 2023-11-03 Exercise | 2023-11-06 4:43 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 8,546 | $1.12 | 1,441,039 (Direct) | View |
| 2023-11-03 Exercise | 2023-11-06 4:43 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 8,546 | $0 | 1,441,039 (Direct) | View |
| 2023-09-29 Exercise | 2023-10-03 7:40 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 12,000 | $1.12 | 1,449,585 (Direct) | View |
| 2023-09-29 Exercise | 2023-10-03 7:40 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 12,000 | $0 | 1,449,585 (Direct) | View |
| 2023-04-04 Option Award | 2023-04-06 8:33 pm | N/A 2033-04-04 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 206,000 | $0 | 206,000 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-27 9:34 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 1,550,116 | $0 | 1,550,116 (Direct) | View |